Valuation: Beijing Konruns Pharmaceutical Co.,Ltd.

Market Cap 4.25B 637M 571M 528M 478M 894M 60.65B 905M 6.32B 2.52B 31.74B 2.39B 2.34B 101B P/E 2024
87.1x
P/E 2025 38.2x
Enterprise Value 3.6B 539M 484M 447M 405M 757M 51.37B 766M 5.35B 2.13B 26.88B 2.02B 1.98B 85.34B EV / Sales 2024
3.92x
EV / Sales 2025 6.2x
Free-Float
50.34%
Yield 2024
2.55%
Yield 2025 0.88%
1 day+2.04%
1 week-2.42%
Current month-15.79%
1 month-7.27%
3 months-13.28%
6 months-25.45%
Current year-31.97%
1 week 26.27
Extreme 26.27
27.97
1 month 26.27
Extreme 26.27
33
Current year 26.27
Extreme 26.27
45.9
1 year 26.27
Extreme 26.27
50.76
3 years 20.07
Extreme 20.07
67.98
5 years 20.07
Extreme 20.07
67.98
10 years 20.07
Extreme 20.07
67.98
Manager TitleAgeSince
President 59 2023-07-19
Director of Finance/CFO 39 2024-08-26
Corporate Officer/Principal 52 2018-12-31
Director TitleAgeSince
Chairman 65 2013-11-30
Chairman 66 2023-07-19
Director/Board Member 39 2011-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/22/26 Buy

Director

150,000 0.0951%
9/22/26 Buy

Chairperson

200,000 0.1268%
11/3/25 Sell

Founder

531,200 0.3368%
Change 5-day change 1-year change 3-year change Capi.($)
+2.04%-2.42%-43.82%-28.65% 624M
+0.50%+1.38%+57.09%+129.96% 1,143B
+0.86%+5.14%+45.00%+86.15% 647B
-0.14%+0.42%+25.69%+105.85% 506B
-0.05%+1.73%+52.74%+67.74% 384B
-0.63%-5.97%+61.93%+37.06% 350B
+0.34%+1.84%+30.70%+54.27% 293B
-0.45%+1.19%+2.89%+26.08% 265B
+0.87%+3.08%+54.69%+72.74% 242B
+0.08%+3.67%+35.05%+107.78% 197B
Average +0.34%+1.32%+32.19%+65.90% 402.82B
Weighted average by Cap. +0.25%+1.55%+44.48%+89.00%

Financials

2024 2025
Net sales 825M 124M 111M 103M 93M 174M 11.79B 176M 1.23B 489M 6.17B 465M 455M 19.59B 915M 137M 123M 114M 103M 193M 13.07B 195M 1.36B 542M 6.84B 515M 504M 21.72B
Net income 42.22M 6.33M 5.68M 5.25M 4.76M 8.89M 603M 8.99M 62.8M 25.01M 316M 23.76M 23.26M 1B 166M 24.89M 22.33M 20.65M 18.7M 34.94M 2.37B 35.36M 247M 98.34M 1.24B 93.41M 91.44M 3.94B
Net Debt -485M -72.71M -65.24M -60.31M -54.63M -102M -6.93B -103M -721M -287M -3.62B -273M -267M -11.5B -649M -97.38M -87.37M -80.77M -73.15M -137M -9.27B -138M -966M -385M -4.85B -365M -358M -15.41B
Projected Income Statement - Annual - Beijing Konruns Pharmaceutical Co.,Ltd.
Logo Beijing Konruns Pharmaceutical Co.,Ltd.
Beijing Konruns Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of drugs. The Company's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is primarily used to prevent and treat perioperative exudate. Its product Miacalcic, is salmon calcitonin, a peptide drug primarily used to regulate calcium metabolism and inhibit osteoclast activity. The Company's products under research include KC1036 for oncology, the analgesic ZY5301, the innovative drug KC1086, and a Pit Viper hemocoagulase injectable for dogs. The Company mainly distributes its products in the domestic market.
Employees
793
Date Price Change Volume
26-10-28 CN¥27.04 +2.04% 1,979,000
26-10-27 CN¥26.50 -4.30% 2,382,900
26-10-26 CN¥27.69 +0.47% 1,752,814
26-10-23 CN¥27.56 +2.04% 2,666,264
26-10-22 CN¥27.01 -2.53% 1,730,122

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Beijing Konruns Pharmaceutical Co.,Ltd.
  1. Stock Market
  2. Stocks
  3. 603590 Stock